Roundtable Roundup: Choosing a Bispecific Antibody for R/R Multiple Myeloma

Publication
Article
Peers & Perspectives in OncologyDecember I, 2024
Pages: 72

In separate, live events, Binod Dhakal, MD, MS; and Laahn H. Foster, MD, polled oncologists on therapeutic options for a patient with multiple myeloma and progressive disease.

CASE SUMMARY

  • A 72-year-old man was diagnosed 6 years ago with multiple myeloma, with 60% plasma cells and translocation 14;20.
  • Medical history: respiratory infections (2 episodes of pneumonia and multiple episodes of bronchitis over prior 10 years)
  • He received 5 prior lines of therapy, most recently chimeric antigen receptor T-cell infusion
  • He now presents with progressive disease (elevated free light chain, creatinine level of 2.3 mg/dL)
  • ECOG performance status: 2
poll 1

CASE UPDATE

Talquetamab is initiated via step-up dosing (SUD) up to 800 μg/kg every 2 weeks (Q2W).

step up talquetamab
poll 2
Recent Videos
1 expert in this video
1 expert in this video
4 experts are featured in this series.
1 expert in this video
1 expert in this video
Related Content